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In this issue of Immunity, the studies by Sutton et al. (2009) and Martin et al. (2009) indicate that gd T cells are
innate cells that rapidly produce interleukin (IL)-17 in response to cytokines or pathogenswithout the need for
T cell receptor engagement.There are compelling reasons to consider
the notion that T cells that express the
gamma-delta T cell receptors (gd TCRs)
are innate cells that critically contribute
to host defense. First of all, in contrast to
conventional ab TCRs and similarly to
innate receptors, the repertoire of gd
TCRs is very limited and directly recog-
nizes poorly defined polymorphic struc-
tures without the requirement for pro-
cessing and presentation by specialized
antigen-presenting cells. In addition, gd
T cells are found in small numbers in
lymphoid tissues but are more abundant
in peripheral tissues. Another striking
feature shared with innate cells is that
within hours upon infection, antigen-naive
gd T cells already produce high amounts
of effector cytokines, including IL-17 and
interferon (IFN)-g that contribute to early
recruitment of more specialized innate
effectors, functional polarization of ab
T cells, and/or direct clearance of in-
vading pathogens (Roark et al., 2008). In
particular, IL-17 is linked to protection
against bacterial and fungal infections
through the recruitment of neutrophils
(Korn et al., 2009) and protection against
type 1 CD4+ T helper (Th1) cell-mediated
pathology in chronic inflammatory dis-
ease (O’Connor et al., 2009). Whereas
the concept of IL-17 production by ab
Th (Th17) cells and the conditions of their
development warranted much attention
over the last few years, the role of IL-17-
producing gd T (gd T-17) cells remained
in the background. In fact, an over-
whelming majority of IL-17-producing
cells in mice are made up of gd T cells
(Awasthi et al., 2009), and these cells are
critically protective in many mouse mod-
els of infection and chronic inflammation
(O’Brien et al., 2008). gd T cells are hetero-
geneous, not only in terms of their poly-
morphic gd TCRs and their localizationbut also in terms of their effector cytokine
profile. It was previously shown that
antigen-naive mice harbor (CD25+
CD122lo) IL-17- and (CD122hi) IFN-g-
producing gd T cell subsets of which the
functional segregation is predetermined
during their development in the thymus
(Shibata et al., 2008; Jensen et al., 2008).
A confusing issue is that upon infection
of antigen-naive mice gd T cells are,
without prior expansion, massively trig-
gered to rapidly produce IL-17, whereas
the pathogen-derived ligands are mainly
unknown. In this issue of Immunity, Mills
and colleagues (Sutton et al., 2009) and
Veldhoen and colleagues (Martin et al.,
2009) propose an unexpected answer to
this question, by suggesting that, in con-
trast to ab Th17 cell function, gd T cells
can be triggered to produce IL-17 upon
innate signals without TCR ligation. The
many recent studies on ab Th cells have
revealed that the development of ab
Th17 cells requires antigen-specific stim-
ulation of naive Th cells in the presence of
Th17 cell-polarizing cytokines produced
by antigen-presenting dendritic cells or
bystander cells (Korn et al., 2009). This
Th17 cell development is initiated in naive
Th cells by the cytokines TGF-b and IL-6
(and autocrine IL-21), which induce the
expression of IL-23 receptor (IL-23R),
chemokine receptor CCR6, and the Th
cell subset-specific transcription factor
RORgt, which is necessary and sufficient
for induction of IL-17. However, these
Th17 cells have to become stable inflam-
matory effector cells through the addi-
tional activation by the cytokines IL-23
and IL-1. Pathogens can induce the
production of these cytokines in many
host cell types upon the triggering of
selected pattern recognition receptors
(PRRs). IL-23 and IL-1 may be selectively
triggered by bacterial lipids ligating Toll-Immunity 3like receptor (TLR) 2 and by fungal b-glu-
cane triggering dectin 1. The surprising
picture drawn by the two present studies
is that the induction of IL-17 production
by gd T cells can be strikingly different
from that of ab Th cells. They show that
the subset of gd T-17 cells display an acti-
vated phenotype, express IL-23R, CCR6,
and RORgt, and are able to rapidly
produce IL-17A (as well as IL-17F, IL-21,
and IL-22) upon immunization in vivo,
features that resemble antigen-experi-
enced ab Th17 cells (Figure 1). Most
strikingly and in sharp contrast to IL-17
production by effector Th17 cells, IL-17-
production by T cells does not need TCR
engagement but can be merely triggered
by the cytokines IL-23 and IL-1, as
produced by pathogen-activated den-
dritic cells as bystander cells (Sutton
et al., 2009) or by the direct triggering of
TLR2 and dectin-1 by pathogens (Martin
et al., 2009).
In line with a previous study showing
that the maintenance of gd T-17 cells
was severely compromised in the ab-
sence of IL-23 but not IL-6 (Lochner
et al., 2008), the study by Mills and
colleagues (Sutton et al., 2009) shows
that the combination of IL-23 and IL-1,
and not IL-6 and TGF-b, induce IL-17 in
gd T cells and that these cytokines are
instrumental as products of cocultured
dendritic cells activated by killed bac-
teria (i.e., Mycobacterium tuberculosis).
An initial unique finding of this study was
that effector cytokine production by gd
T cells did not require TCR ligation by
anti-CD3, albeit that the amounts of IL-17
were substantially lower in the absence of
anti-CD3. They subsequently applied a
mouse model of experimental encephalo-
myelitis (EAE), which is known to depend
on brain antigen (MOG)-specific T cells
and IL-17. After immunization with MOG1, August 21, 2009 ª2009 Elsevier Inc. 181
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Engagement of the T cell receptor (TCR) of ab T cells selects their repertoire in the thymus and allows them
to respond in the periphery to signals that polarize their function, such as the cytokine IL-23, which stabi-
lizes IL-17 production in T cells, or IL-12, which promotes IFN-g production (bottom left and right).
Antigen-naive mice gd T cells, however, harbor CD122loCD25hi gd T (gd T-17) cells that, in contrast to
ab T cells and CD122hi gd T cells (that contain IFN-g producers), are predetermined in the thymus to
become IL-17 producers without TCR engagement (top left). New studies (Sutton et al., 2009; Martin
et al., 2009) underscore TCR independency of gd T-17 cells, also at their functional level (top right, green
cells). They show that gd T-17 cells additionally express the receptor for IL-23, and the innate receptors
TLR2 and dectin-1, which recognize archetypical bacterial and fungal constituents. These gd T-17 cells
use these receptors to rapidly produce IL-17 in response to bystander cell-derived IL-23 and to bacteria
and fungi without concomitant TCR stimulation. One of the roles of gd T-17-derived IL-17 may be indirect
(via potentiation of IL-23 production in antigen-presenting dendritic cells) or direct amplification of IL-17
production in Th17 cells (curved arrows).in complete Freunds’ adjuvant (containing
mycobacterial compounds) and during
clinical symptoms, they found enhanced
amounts of IL-1 and IL-23p19 mRNA
that coincided with elevated IL-17 mRNA
expression and the detection of gd T-17
cells during the development of EAE. A
contribution of the gd T-17 cells to EAE
pathology was substantiated by experi-
ments in mice lacking gd T cells or IL-1
receptors, with delayed onset of EAE
and less severe symptoms for the mice,
and by transfer experiments. Moreover,
these transfer experiments revealed that
cooperation between gd T-17 cells and
CD4+ T cells is vital for EAE development.
This observation inspired a subsequent
series of in vitro and in vivo experiments
indicating that IL-23 and IL-1 promote
the innate production of IL-17 by gd
T cells and that IL-17 subsequently
amplifies IL-17 production by antigen-182 Immunity 31, August 21, 2009 ª2009 Elsspecific Th17 cells, either by the direct
interaction with CD4+ T cells or, indirectly,
by amplifying IL-23 production by den-
dritic cells. The data suggest that gd
T-17 cells have a pathogenic role early in
EAE development, among others by con-
trolling the generation of Th17 cells. The
control of Th17 cell function by gd T-17
cells is an unexpected and attractive
concept that requires further confirma-
tion.
Veldhoen and colleagues (Martin et al.,
2009) detected early gd T-17 cells in mice,
in particular after immunization with M.
tuberculosis or C. albicans hyphae or
with bacterial lipid TLR2 agonist (and not
with TLR4 agonist) and with fungal b-glu-
cane, the dectin-1 agonist. They share
with the study by Mills and colleagues
the finding that gd T-17 T cells produce
IL-17 in absence of gd TCR ligation.
However, elaborating on previous reportsevier Inc.on the expression of TLR2 on gd T cells,
they show that only CCR6+ gd T cells
express TLR2 and/or dectin-1 and pro-
duce IL-17 upon direct ligation by TLR2
and dectin-1 agonists and that this IL-17
production is amplified by IL-23. Interest-
ingly, their experiments showed that mere
IL-23 addition also amplifies IL-17 pro-
duction, even more strongly than TLR2-
or dectin-1 ligation, and that the combina-
tion of IL-23 and innate receptor ligation
was best. Transfer of gd T cells into
TLR2-deficient hosts challenged with a
bacterial TLR2 agonist elegantly under-
scored direct pathogen recognition by
gd T-17 cells in vivo.
Taken together, the two present studies
highlight the innate nature of the gd T-17
cell subset by showing its selective ex-
pression of IL-23R, TLR2, and dectin-1
and its responsiveness to IL-23 and IL-1
produced by accessory cells activated
by bacterial and fungal infection as well
as its direct responsiveness to bacterial
TLR2- and fungal dectin-1 agonists. gd
T-17 cells act like other innate immune
cells by directly responding to pathogens
or to cytokines produced by cells in in-
fected tissue and, as a result, producing
cytokines that amplify the function of
other innate or adaptive immune cells. A
striking consequence of the new findings
is that the role of gd TCRs in gd T cell-
mediated host defense may be redun-
dant. The role of gd TCRs in gd T-17 cell
function was already suggested to be
redundant at the level of T cell develop-
ment with the finding that gd T-17
cells form a unique gd T cell subset of
cells that become predetermined IL-17
producers in the thymusseeminglywithout
prior TCRengagement and, consequently,
without positive and negative TCR selec-
tion (Jensen et al., 2008). Themechanisms
underlying the development of gd T-17
cells in the thymus and the way these cells
transit from a naive into activated pheno-
type in antigen-naive mice is a mystery.
The knowledge that these cells can be
activated in the periphery by cytokines
and innate signals without TCR engage-
ment may provide alternative approaches
to these questions. However, TCR en-
gagement by anti-CD3 on lymph node
CD122lo cells does result in IL-17 produc-
tion (Jensen et al., 2008) even in the
absence of IL-23 and IL-1, stressing gd
TCRs can be involved in gd T-17 function.
Therefore, the deciphering of relative
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Previewsroles of cytokines and PRR and TCR
ligands in the development of gd T cells
and their function in protection and
pathology is a great challenge for future
research.
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